Trials / Approved For Marketing
Approved For MarketingNCT05344508
An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis
Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Insmed Incorporated · Industry
- Sex
- All
- Age
- 12 Years – 85 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to allow early access to brensocatib for participants with non-cystic fibrosis bronchiectasis (NCFBE) who have successfully completed the INS1007301 ASPEN Clinical trial.
Detailed description
Participants will receive brensocatib 10 mg, oral tablets, once daily.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brensocatib | Brensocatib tablets |
Timeline
- First posted
- 2022-04-25
- Last updated
- 2025-11-04
Source: ClinicalTrials.gov record NCT05344508. Inclusion in this directory is not an endorsement.